Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

A Corrigendum to this article was published on 16 February 2011

This article has been updated


The question of whether tumorigenic cancer stem cells exist in human melanomas has arisen in the last few years1. Here we show that in melanomas, tumour stem cells (MTSCs, for melanoma tumour stem cells) can be isolated prospectively as a highly enriched CD271+ MTSC population using a process that maximizes viable cell transplantation1,2. The tumours sampled in this study were taken from a broad spectrum of sites and stages. High-viability cells isolated by fluorescence-activated cell sorting and re-suspended in a matrigel vehicle were implanted into T-, B- and natural-killer-deficient Rag2−/−γc−/− mice. The CD271+ subset of cells was the tumour-initiating population in 90% (nine out of ten) of melanomas tested. Transplantation of isolated CD271+ melanoma cells into engrafted human skin or bone in Rag2−/−γc−/− mice resulted in melanoma; however, melanoma did not develop after transplantation of isolated CD271 cells. We also show that in mice, tumours derived from transplanted human CD271+ melanoma cells were capable of metastatsis in vivo. CD271+ melanoma cells lacked expression of TYR, MART1 and MAGE in 86%, 69% and 68% of melanoma patients, respectively, which helps to explain why T-cell therapies directed at these antigens usually result in only temporary tumour shrinkage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Isolation of melanoma tumour stem cells (MTSCs) expressing CD271 P75(NGFR) from melanoma patients.
Figure 2: MTSCs induce tumours in humanized mouse models.
Figure 3: Most melanomas contain CD271 + tumour cells that either completely or partially lack expression of melanoma tumour antigens.

Similar content being viewed by others

Change history

  • 16 February 2011

    Nature 466, 133–137 (2010) In this Letter, Fig. 1b and Table 2 (summarizing experiments presented in Supplementary Figs 2–4 and 7–9) contained an error reflecting the total number of tumours formed, and the total number of injections with CD271+ cells isolated directly from patients (26 out of 37). The correct number is 25 out of 38.


  1. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008)

    Article  ADS  CAS  Google Scholar 

  2. Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016–14021 (2009)

    Article  ADS  CAS  Google Scholar 

  3. Weissman, I. Stem cell research: paths to cancer therapies and regenerative medicine. J. Am. Med. Assoc. 294, 1359–1366 (2005)

    Article  CAS  Google Scholar 

  4. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003)

    Article  ADS  CAS  Google Scholar 

  5. Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004)

    Article  CAS  Google Scholar 

  6. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003)

    CAS  Google Scholar 

  7. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158–10163 (2007)

    Article  ADS  CAS  Google Scholar 

  8. O’Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007)

    Article  ADS  Google Scholar 

  9. Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007)

    Article  ADS  CAS  Google Scholar 

  10. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001)

    Article  ADS  CAS  Google Scholar 

  11. Baroffio, A., Dupin, E. & Le Douarin, N. M. Clone-forming ability and differentiation potential of migratory neural crest cells. Proc. Natl Acad. Sci. USA 85, 5325–5329 (1988)

    Article  ADS  CAS  Google Scholar 

  12. Morrison, S. J., White, P. M., Zock, C. & Anderson, D. J. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 96, 737–749 (1999)

    Article  CAS  Google Scholar 

  13. Chesa, P. G., Rettig, W. J., Thomson, T. M., Old, L. J. & Melamed, M. R. Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J. Histochem. Cytochem. 36, 383–389 (1988)

    Article  CAS  Google Scholar 

  14. Pietra, G. et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 21, 793–801 (2009)

    Article  CAS  Google Scholar 

  15. Iwamoto, S., Odland, P. B., Piepkorn, M. & Bothwell, M. Evidence that the p75 neurotrophin receptor mediates perineural spread of desmoplastic melanoma. J. Am. Acad. Dermatol. 35, 725–731 (1996)

    Article  CAS  Google Scholar 

  16. Marchetti, D., Menter, D., Jin, L., Nakajima, M. & Nicolson, G. L. Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int. J. Cancer 55, 692–699 (1993)

    Article  CAS  Google Scholar 

  17. Truzzi, F. et al. Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. J. Invest. Dermatol. 128, 2031–2040 (2008)

    Article  CAS  Google Scholar 

  18. Hérin, M. et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 39, 390–396 (1987)

    Article  Google Scholar 

  19. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991)

    Article  ADS  CAS  Google Scholar 

  20. Rosenberg, S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl Cancer Inst. 88, 1635–1644 (1996)

    Article  CAS  Google Scholar 

  21. Cormier, J. N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37–44 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Scheibenbogen, C. et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23, 275–281 (2000)

    Article  CAS  Google Scholar 

  23. Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008)

    Article  ADS  CAS  Google Scholar 

  24. La Porta, C. Cancer stem cells: lessons from melanoma. Stem Cell Rev. 5, 61–65 (2009)

    Article  CAS  Google Scholar 

  25. Eaves, C. J. Cancer stem cells: Here, there, everywhere? Nature 456, 581–582 (2008)

    Article  ADS  CAS  Google Scholar 

  26. Passegué, E., Rafii, S. & Herlyn, M. Cancer stem cells are everywhere. Nature Med. 15, 23 (2009)

    Article  Google Scholar 

  27. Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822–829 (2009)

    Article  CAS  Google Scholar 

  28. Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197 (2000)

    Article  ADS  CAS  Google Scholar 

  29. Miyamoto, T., Weissman, I. L. & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521–7526 (2000)

    Article  ADS  CAS  Google Scholar 

  30. Akala, O. O. et al. Long-term haematopoietic reconstitution by Trp53−/−p16Ink4a−/−p19Arf−/− multipotent progenitors. Nature 453, 228–232 (2008)

    Article  ADS  CAS  Google Scholar 

Download references


We thank J. Bueno and S. Hicks for obtaining patient consent and specimens; K. Montgomery for immunohistochemistry analyses; D. Kim for NSG bone-grafted mice; K. Chan, L. Ailles and C. Park for advice and help in FACS and tumour transplantation assays; L. Cohen for MAGE antibodies; L. Jerabek, T. Storm and A. Mosley for laboratory and mouse management; P. Lovelace for FACS management; A. Olson for help with microscopy; all members of the Weissman Laboratory for experimental suggestions; and M. Clarke and members of his laboratory for critical discussions and reading. This research was initially supported in part by the American Cancer Society fellowship and in part by NIH F32 CA126252 NRSA fellowship to A.D.B.; the Virginia & D.K. Ludwig Fund for Cancer Research to I.L.W.; NIH/NCRR CTSA grant UL1 RR025744 to Stanford Spectrum M.v.d.R.; The Oak Foundation and NIH 1RC2 DE02077-01 to M.T.L.; the Oak Foundation and Ellenburg Faculty Scholar Endowment to G.P.Y.

Author information

Authors and Affiliations



A.D.B., M.T.L. and I.L.W. designed research; A.D.B. and O.V.R. performed research; M.v.d.R. and A.D.B. performed immunohistochemical and pathological analysis; S.M.S. provided clinical information; D.L.J., B.J. and M.J.K. provided human surgical melanoma tissues; D.P.L., P.D.B., G.P.Y. and M.T.L. provided humanized skin mouse model; A.D.B. and O.V.R. analysed the data; A.D.B. and I.L.W. wrote the paper.

Corresponding authors

Correspondence to Alexander D. Boiko or Irving L. Weissman.

Ethics declarations

Competing interests

I.L.W. was a member of the scientific advisory board of Amgen and owns significant Amgen stock; he co-founded and consulted for Systemix; he is a co-founder and director of Stem Cells, Inc.; and co-founded Cellerant, Inc. None of these companies is in the cancer stem cell field, at least while I.L.W. was an advisor or held the stock.

Supplementary information

Supplementary Information

This file contains Supplementary Tables 1-3, Supplementary Figures 1-28 and a list of the antibodies that were used in FACS analysis and cell sorting. The Supplementary Information file was corrected on 17 February 2011 (PDF 16088 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boiko, A., Razorenova, O., van de Rijn, M. et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466, 133–137 (2010).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer